misoprostol has been researched along with Renal-Insufficiency* in 5 studies
1 review(s) available for misoprostol and Renal-Insufficiency
Article | Year |
---|---|
Non-steroidal anti-inflammatory drugs and renal function.
The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a range of renal effects, including interference with fluid and electrolyte homoeostasis. Common adverse effects are generally mild and transient; less common but more severe effects include reversible renal insufficiency, interstitial nephritis and papillary necrosis. Any of these effects can influence the clinical course of patients at risk because of illness, debility or age. Acute renal failure associated with NSAID use has been reported to account for up to 15.6% of cases of drug-induced renal failure. NSAID-induced haemodynamic renal failure is virtually always reversible with appropriate management; the relatively rare complications of interstitial nephritis and papillary necrosis are more often irreversible. NSAID-related impairment of kidney function is probably due in large part to inhibition of prostaglandin synthesis. Use of a prostaglandin E1 (PGE1) analogue has been suggested to prevent some of the adverse renal effects of NSAIDs in patients at high risk, an interesting possibility that deserves further evaluation. Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Glomerular Filtration Rate; Humans; Misoprostol; Renal Insufficiency | 1995 |
1 trial(s) available for misoprostol and Renal-Insufficiency
Article | Year |
---|---|
Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function.
The disposition of misoprostol acid, the active metabolite of misoprostol, was studied in 48 subjects with various degrees of renal function after administration of a single 400 microgram oral dose of misoprostol. Subjects were assigned to one of four treatment groups: group 1, normal renal function with creatinine clearance (CLCR) 80-140 mL/min/1.73 m2; group 2, mild renal impairment with CLCR 50-79 mL/min/1.73 m2; group 3, moderate renal impairment with CLCR 20-49 mL/min/1.73 m2 or group 4, end stage renal disease (ESRD) patients maintained on hemodialysis. The maximum plasma concentration (Cmax) and time to reach Cmax (tmax) for misoprostol acid tended to be larger in group 4 subjects; however, it failed to reach statistical significance. Although not statistically significant, in group 4 subjects the terminal half-life (t1/2) of misoprostol acid was almost twice as large (1.27 +/- 0.77 h) as in groups 1, 2, and 3 (0.70 +/- 0.72, 0.72 +/- 0.67, and 0.73 +/- 0.45 h, respectively). Misoprostol acid's total area under the plasma concentration curve (AUC0 infinity) was larger in group 4 subjects (1173.5 +/- 487.4 pg.h/mL) as compared with groups 1, 2, and 3 (421.4 +/- 263.1, 418.9 +/- 114.5, and 377.0 +/- 145.2 pg.h/mL, respectively; P < .05). The apparent total body clearance (CL) of misoprostol acid was statistically significantly smaller in group 4 subjects (0.094 +/- 0.044 L/kg/min) as compared only with group 3 subjects (0.284 +/- 0.102 L/kg/min). The dose of misoprostol may need to be reduced in ESRD patients on prolonged hemodialysis to prevent unnecessary high plasma levels of misoprostol acid and to avoid possible dose-related adverse effects. Topics: Acute Kidney Injury; Creatinine; Female; Half-Life; Humans; Kidney; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Misoprostol; Renal Insufficiency | 1995 |
3 other study(ies) available for misoprostol and Renal-Insufficiency
Article | Year |
---|---|
Second trimester medical abortion in a primigravida with lupus nephritis and rapidly progressive renal failure: challenges and outcome.
In the second trimester, medical abortion is preferred as it is less invasive, and the surgical method carries more risk. There is a paucity of published literature on medical abortion in women with renal failure requiring haemodialysis. We came across a woman who presented with rapidly progressive renal failure at 18 weeks of gestation and required therapeutic abortion. We are reporting the challenges, outcomes, and precautions to be taken while performing a medical abortion in such a case. Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Induced; Female; Humans; Lupus Nephritis; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Renal Insufficiency; Treatment Outcome | 2021 |
The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis.
Indomethacin has been shown to have adverse effects on renal function in patients with well-compensated alcoholic cirrhosis. The aim of this study was to determine whether an oral prostaglandin E1 analogue, misoprostol, could prevent this indomethacin-induced renal dysfunction.. Six patients with well-compensated alcoholic cirrhosis were studied. Renal hemodynamics and tubular function were assessed by clearance techniques before and after an oral dose of (i) 50 mg of indomethacin alone (I50), and (ii) a combination of I50 and 200 micrograms of misoprostol.. I50 produced a significant reduction in glomerular filtration rate, a fall in effective renal plasma flow and an increase in renal vascular resistance. Two hundred micrograms of misoprostol was able to abolish the deleterious renal effects of indomethacin totally, yielding an increase in glomerular filtration rate and effective renal plasma flow and a decrease in renal vascular resistance as well as an increase in urinary volume and urinary sodium excretion. These beneficial effects were maximal in the hour immediately following medication, but were only transient, and this may be a limiting factor in its clinical use.. If the beneficial renal effects of misoprostol could be confirmed after chronic administration, then the vasodilatory, natriuretic and diuretic potential of 200 micrograms of misoprostol could be of potential therapeutic value in patients with well-compensated alcoholic cirrhosis who require non-steroidal anti-inflammatory drug therapy. Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Interactions; Drug Therapy, Combination; Glomerular Filtration Rate; Hemodynamics; Humans; Indomethacin; Kidney; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Misoprostol; Prostaglandins, Synthetic; Renal Insufficiency; Sodium; Vascular Resistance | 1995 |
Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure.
Prostaglandins play an important role in the maintenance of renal hemodynamics and water excretion in cirrhosis. To investigate whether the administration of prostaglandins improves renal function in cirrhotic patients with ascites, 16 patients with functional renal failure and/or dilutional hyponatremia were given oral misoprostol, a prostaglandin E1 analogue (200 micrograms/6 h for 4 days; n = 9) or intravenous prostaglandin E2 (0.5 microgram/min for 1 h followed by 1 microgram/min for another hour; n = 7). The administration of misoprostol did not induce significant changes in the glomerular filtration rate (59 +/- 11 vs. 54 +/- 11 ml/min), sodium excretion (4.0 +/- 1.3 vs. 4.1 +/- 2.1 microEq/min), and free water clearance (2.4 +/- 0.8 vs. 2.1 +/- 0.9 ml/min), nor did it improve the natriuretic response to an intravenous bolus of 40 mg of furosemide (486 +/- 124 vs. 406 +/- 88 microEq/min). Similarly, an infusion of prostaglandin E2 did not induce significant changes in the glomerular filtration rate (baseline: 33 +/- 6; 0.5 microgram/min: 31 +/- 5; 1 microgram/min: 31 +/- 6 ml/min) and sodium excretion (5.7 +/- 2.7; 3.2 +/- 1.4; and 1.5 +/- 0.7 microEq/min, respectively), whereas free water clearance decreased significantly (1.1 +/- 0.7; 0.5 +/- 0.5; and -0.1 +/- 0.2 ml/min, respectively, p < 0.05). These results indicate that oral misoprostol or the intravenous infusion of prostaglandin E2 do not improve renal function in cirrhosis with ascites. Topics: Administration, Oral; Adult; Aged; Ascites; Dinoprostone; Diuresis; Female; Glomerular Filtration Rate; Humans; Hyponatremia; Infusions, Intravenous; Kidney; Liver Cirrhosis; Male; Middle Aged; Misoprostol; Natriuresis; Renal Circulation; Renal Insufficiency | 1993 |